CN112334134A - 氨氯地平制剂 - Google Patents
氨氯地平制剂 Download PDFInfo
- Publication number
- CN112334134A CN112334134A CN201980039595.2A CN201980039595A CN112334134A CN 112334134 A CN112334134 A CN 112334134A CN 201980039595 A CN201980039595 A CN 201980039595A CN 112334134 A CN112334134 A CN 112334134A
- Authority
- CN
- China
- Prior art keywords
- amlodipine
- suspension
- minutes
- mixture
- benzoate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656188P | 2018-04-11 | 2018-04-11 | |
| US62/656,188 | 2018-04-11 | ||
| PCT/US2019/027044 WO2019200143A1 (en) | 2018-04-11 | 2019-04-11 | Amlodipine formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112334134A true CN112334134A (zh) | 2021-02-05 |
Family
ID=68161047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980039595.2A Pending CN112334134A (zh) | 2018-04-11 | 2019-04-11 | 氨氯地平制剂 |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US10799453B2 (https=) |
| EP (1) | EP3773574A4 (https=) |
| JP (1) | JP7456933B2 (https=) |
| CN (1) | CN112334134A (https=) |
| CA (1) | CA3096101A1 (https=) |
| WO (1) | WO2019200143A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3960158B1 (en) | 2016-10-07 | 2025-05-21 | Silvergate Pharmaceuticals, Inc. | Amlodipine formulations |
| WO2019200143A1 (en) | 2018-04-11 | 2019-10-17 | Silvergate Pharmaceuticals, Inc. | Amlodipine formulations |
| CN112716903B (zh) * | 2021-01-18 | 2023-03-21 | 广州一品红制药有限公司 | 一种氨氯地平干混悬剂及其制备方法 |
| US11452690B1 (en) | 2021-01-27 | 2022-09-27 | ECI Pharmaceuticals, LLC | Oral liquid compositions comprising amlodipine besylate and methods of using the same |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060030602A1 (en) * | 2004-03-16 | 2006-02-09 | Sepracor Inc. | (S)-amlodipine malate |
| US20110294860A1 (en) * | 2008-12-17 | 2011-12-01 | Medrx Co., Ltd. | Aqueous oral preparation of stable amlodipine |
| CN102746215A (zh) * | 2011-04-18 | 2012-10-24 | 张兆勇 | 一种制备高纯度盐酸贝尼地平的方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK161312C (da) | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
| GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| US6057344A (en) | 1991-11-26 | 2000-05-02 | Sepracor, Inc. | Methods for treating hypertension, and angina using optically pure (-) amlodipine |
| US6333342B1 (en) | 1998-11-04 | 2001-12-25 | Isotechnika, Inc | Methods of pharmacological treatment using S(−) amlodipine |
| CN1100038C (zh) | 2000-02-21 | 2003-01-29 | 张喜田 | 氨氯地平对映体的拆分 |
| PL362660A1 (en) | 2000-12-29 | 2004-11-02 | Pfizer Limited | Process for making amlodipine maleate |
| WO2002053540A1 (en) | 2000-12-29 | 2002-07-11 | Pfizer Limited | Aspartate derivative of amlodipine as calcium channel antagonist |
| AT5874U1 (de) | 2000-12-29 | 2003-01-27 | Bioorg Bv | Pharmazeutische zubereitungen enthaltend amlodipinmaleat |
| EP1309557B9 (en) | 2000-12-29 | 2006-11-15 | Pfizer Limited | Amlodipine hemimaleate |
| MXPA03005882A (es) | 2000-12-29 | 2005-04-19 | Pfizer Ltd | Derivado amida de amlodipina. |
| EP1309556B1 (en) | 2000-12-29 | 2004-11-24 | Pfizer Limited | Amlodipine fumarate |
| US6653481B2 (en) | 2000-12-29 | 2003-11-25 | Synthon Bv | Process for making amlodipine |
| CA2433193C (en) | 2000-12-29 | 2006-01-31 | Pfizer Limited | Amide derivative of amlodipine |
| US6680334B2 (en) | 2001-08-28 | 2004-01-20 | Pfizer Inc | Crystalline material |
| IL161448A0 (en) | 2001-10-24 | 2004-09-27 | Sepracor Inc | Method of resolving amlodipine racemate |
| KR100496436B1 (ko) | 2002-07-30 | 2005-06-20 | 씨제이 주식회사 | 암로디핀의 유기산염 |
| KR100538641B1 (ko) | 2002-07-30 | 2005-12-22 | 씨제이 주식회사 | 암로디핀의 유기산염 |
| KR100467669B1 (ko) | 2002-08-21 | 2005-01-24 | 씨제이 주식회사 | 암로디핀의 유기산염 |
| AU2003253460A1 (en) | 2002-09-19 | 2004-04-08 | Cj Corporation | Crystalline organic acid salt of amlodipine |
| CA2559670A1 (en) | 2003-04-14 | 2004-10-28 | Gabor Pragai | Stable amlodipine maleate formulations |
| WO2005079772A2 (en) | 2004-02-18 | 2005-09-01 | Sepracor Inc. | Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension |
| WO2005099699A1 (en) | 2004-04-07 | 2005-10-27 | Sepracor Inc. | Combination of (s)-amlodipine and a beta-blocker, and methods for reducing hypertension |
| WO2006059217A1 (en) | 2004-12-01 | 2006-06-08 | Ranbaxy Laboratories Limited | Stable solid dosage forms of amlodipine besylate and processes for their preparation |
| EP1831166B1 (en) | 2004-12-02 | 2010-10-20 | SK Chemicals, Co., Ltd. | Optical resolution method of amlodipine |
| GT200600371A (es) | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
| US8158146B2 (en) | 2005-09-28 | 2012-04-17 | Teva Pharmaceutical Industries Ltd. | Stable combinations of amlodipine besylate and benazepril hydrochloride |
| CN101522174A (zh) | 2006-05-10 | 2009-09-02 | 赢创德固赛有限责任公司 | 辊压热解制备的二氧化硅在药物组合物中的应用 |
| CA2655596C (en) * | 2006-06-27 | 2011-10-25 | Biovail Laboratories International Srl | Multiparticulate osmotic delivery system |
| DK2200588T3 (da) | 2007-09-25 | 2019-07-01 | Solubest Ltd | Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf |
| CN101416966B (zh) | 2007-10-22 | 2010-11-10 | 鲁南制药集团股份有限公司 | 一种治疗高血压的药物组合物 |
| KR20100052262A (ko) | 2008-11-10 | 2010-05-19 | (주)아모레퍼시픽 | 난용성 약물의 나노입자를 포함하는 분말의 제조방법, 그에의해 제조된 분말 및 이를 포함하는 약학적 조성물 |
| CN101843615A (zh) | 2010-06-25 | 2010-09-29 | 包丽昕 | 含有缬沙坦和苯磺酸氨氯地平的分散片及其制备方法 |
| CN102370965A (zh) | 2010-08-11 | 2012-03-14 | 南京先宇科技有限公司 | 一种含有左旋氨氯地平药学上可接受的盐与培哚普利药学上可接受的盐的药物组合物 |
| CN102018708A (zh) | 2010-12-12 | 2011-04-20 | 林飞 | 包含氨氯地平和阿托伐他汀镁的药物组合物 |
| CN102114017A (zh) | 2011-01-05 | 2011-07-06 | 王定豪 | 包含氨氯地平和培哚普利的药物组合物及其应用 |
| WO2013191668A1 (en) * | 2012-06-22 | 2013-12-27 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Compositions preventing hypertension comprising soluplus |
| US20140024723A1 (en) | 2012-07-17 | 2014-01-23 | Dow Global Technologies Llc | Composition comprising an organic liquid diluent and a specific hydroxypropyl methylcellulose |
| GB2529605B (en) * | 2014-06-03 | 2018-03-21 | Essential Pharmaceuticals Ltd | Pharmaceutical composition |
| EP3960158B1 (en) | 2016-10-07 | 2025-05-21 | Silvergate Pharmaceuticals, Inc. | Amlodipine formulations |
| WO2019200143A1 (en) | 2018-04-11 | 2019-10-17 | Silvergate Pharmaceuticals, Inc. | Amlodipine formulations |
-
2019
- 2019-04-11 WO PCT/US2019/027044 patent/WO2019200143A1/en not_active Ceased
- 2019-04-11 CA CA3096101A patent/CA3096101A1/en active Pending
- 2019-04-11 CN CN201980039595.2A patent/CN112334134A/zh active Pending
- 2019-04-11 US US16/381,575 patent/US10799453B2/en active Active
- 2019-04-11 EP EP19784696.7A patent/EP3773574A4/en active Pending
- 2019-04-11 JP JP2020554193A patent/JP7456933B2/ja active Active
-
2020
- 2020-10-09 US US17/067,396 patent/US11471409B2/en active Active
-
2021
- 2021-06-11 US US17/345,943 patent/US11484498B2/en active Active
-
2022
- 2022-08-22 US US17/892,738 patent/US11701326B2/en active Active
-
2023
- 2023-05-30 US US18/203,266 patent/US11918685B2/en active Active
-
2024
- 2024-01-24 US US18/420,901 patent/US12383498B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060030602A1 (en) * | 2004-03-16 | 2006-02-09 | Sepracor Inc. | (S)-amlodipine malate |
| US20110294860A1 (en) * | 2008-12-17 | 2011-12-01 | Medrx Co., Ltd. | Aqueous oral preparation of stable amlodipine |
| CN102746215A (zh) * | 2011-04-18 | 2012-10-24 | 张兆勇 | 一种制备高纯度盐酸贝尼地平的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20210308049A1 (en) | 2021-10-07 |
| WO2019200143A1 (en) | 2019-10-17 |
| US11484498B2 (en) | 2022-11-01 |
| US20220401363A1 (en) | 2022-12-22 |
| EP3773574A4 (en) | 2022-03-02 |
| JP7456933B2 (ja) | 2024-03-27 |
| US11918685B2 (en) | 2024-03-05 |
| US20230338287A1 (en) | 2023-10-26 |
| US20190314279A1 (en) | 2019-10-17 |
| CA3096101A1 (en) | 2019-10-17 |
| US20240252433A1 (en) | 2024-08-01 |
| EP3773574A1 (en) | 2021-02-17 |
| US12383498B2 (en) | 2025-08-12 |
| US20210023003A1 (en) | 2021-01-28 |
| US11471409B2 (en) | 2022-10-18 |
| JP2021520367A (ja) | 2021-08-19 |
| US11701326B2 (en) | 2023-07-18 |
| US10799453B2 (en) | 2020-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12336984B2 (en) | Amlodipine formulations | |
| CN108472252B (zh) | 赖诺普利制剂 | |
| US12383498B2 (en) | Amlodipine formulations | |
| ES2863988T3 (es) | Formulaciones farmacéuticas con mejor solubilidad y estabilidad |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |